Inspector General Orders DEA to Halt Warrantless Searches at Airports and Transportation Hubs

The US Drug Enforcement Administration (DEA) has been directed to cease conducting warrantless searches of travelers at airports and other transportation hubs.

The directive, issued by the Justice Department’s Office of the Inspector General (IG), stems from an investigation that identified significant deficiencies in DEA practices.

The IG’s investigation revealed that DEA agents lacked sufficient training and frequently failed to properly document their search activities, as required by agency policy. Inspector General Michael E. Horowitz criticized the agency for its failure to track data on consensual encounters and assess the effectiveness of its interdiction efforts, stating that these shortcomings raise serious concerns about the efficient use of law enforcement resources.
Continue reading

Study: Cannabigerol (CBG) May Treat Inflammation, Pain, and Neurodegenerative Disorders

A new study published in the journal Molecules shines a spotlight on cannabigerol (CBG), a non-psychoactive cannabinoid that’s rapidly gaining attention for its therapeutic possibilities.

Unlike THC, which is associated with the “high” associated with cannabis use, CBG offers potential medical benefits without intoxication, similar to CBD, making it a compelling candidate for clinical use.

Conducted by researchers from the United States and China, the review explores CBG’s molecular mechanisms and its ability to modulate key physiological processes. “CBG does not induce intoxication, making it an attractive option in the clinic,” the authors note. The study highlights CBG’s interactions with the endocannabinoid system, particularly CB1 and CB2 receptors, as well as transient receptor potential (TRP) channels and α2-adrenoceptors. These pathways suggest that CBG could alleviate inflammation, pain, and neurodegenerative conditions.
Continue reading

Study: CBD-Rich Cannabis Shows Promise in Treating Autism Symptoms

A new systematic review published in the International Journal of Molecular Sciences explores the potential role of cannabidiol (CBD)-rich cannabis in managing symptoms of autism spectrum disorder (ASD).

The study, conducted by researchers from LUM University, G. d’Annunzio University, and the Università Politecnica delle Marche, highlights both the promise and the limitations of this emerging treatment.

ASD is a lifelong neurological condition with limited treatment options, driving interest in alternative therapies such as phytocannabinoids derived from cannabis. This review assessed studies from 2020 onward that focused on individuals with ASD treated with CBD-rich cannabis. Researchers analyzed data from four studies involving 353 participants across Israel, Turkey, and Brazil.
Continue reading

CA$443 Million in Legal Marijuana Sold in Canada in September, Resulting in Over $80 Million in Tax Revenue

Legal marijuana sales in Canada saw a noticeable drop from August to September, but remained on par with previous months.

Licensed marijuana supplies in Canada sold CA$443.9 million worth of product in September, according to data released by Statistics Canada. Although this is a decrease from the CA$475 million sold in August, it’s similar to the CA$453 million sold in July and the CA$433 million sold in June. September sales generated around $88 million in tax revenue.

In September, Ontario had the largest share of marijuana since, with CA$177 million in sales. Alberta came second in sales with CA$76 million, followed by British Columbia at $69 million and Quebec at $55 million. Of these provinces, only British Columbia saw sales increase from August to September.
Continue reading

Study Finds Cannabidiol (CBD) Modulates Gut Microbiota to Mitigate Rheumatoid Arthritis Symptoms

A study published in the journal Phytomedicine, conducted by researchers from the China-Japan Friendship Hospital, investigates how cannabidiol (CBD) influences gut microbiota and metabolic pathways to alleviate symptoms of rheumatoid arthritis (RA).

Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, affecting multiple systems in the body”, states the study’s abstract. “Cannabidiol (CBD) is one of the most medically valuable active ingredients in cannabis. At present, CBD has been shown to alleviate the progression of RA; however, owing to its multiple targets, the mechanism of CBD is not clear.”

For the study, researchers “explored the mechanism by which CBD inhibits RA progression.”
Continue reading

Federal Marijuana Banking Legislation Could Still Pass By Year’s End, But Time is Running Out

Efforts to pass the SAFE or SAFER Banking Act during the lame duck session of Congress are gaining momentum, though time is running out.

The Secure and Fair Enforcement (SAFE) Banking Act currently has 131 sponsors in the U.S. House of Representatives, more than any other marijuana-related bill in Congress. The updated Secure and Fair Enforcement Regulation (SAFER) Banking Act in the Senate has 36 sponsors and was approved late last year by the Senate Banking Committee with bipartisan support.

Both measures would establish explicit federal protections for banks and credit unions that work with marijuana businesses operating legally under state law. They would also allow state-legal marijuana businesses to take standard IRS tax deductions. With the measures set to expire at the end of the year and a new Congress convening in January, proponents are racing against the clock to secure passage.
Continue reading

Medical Marijuana Legalized in 39 States: A State-By-State Breakdown

39 states—78% of the entire country—have legalized medical marijuana.

In 1996, California became the first state to legalize medical marijuana, paving the way for nationwide reform. In the 28 years since, 38 additional states have enacted similar programs, with several others also allowing low-THC marijuana oil for limited use. Nebraska was the most recent, with voter approving medical marijuana legalization in this month’s election, with the law taking effect on December 12.

Here’s a comprehensive look at all 39 states with medical marijuana programs, highlighting possession limits, the availability of licensed dispensaries, and home cultivation rules.
Continue reading

Florida Issues 22 New Medical Marijuana Licenses After Lengthy Wait, State Now Has Over 700 Dispensaries

Florida’s Office of Medical Marijuana Use has issued letters of intent to approve licenses for 22 companies vying to operate as Medical Marijuana Treatment Centers (MMTCs).

These approvals come after a months-long wait for the 74 applicants who initially submitted their applications in April 2023. The companies granted licenses include:
Continue reading

Nebraska Judge Dismisses Legal Challenge to Medical Marijuana Initiatives Approved by Voters

Lancaster County District Court Judge Susan Strong has dismissed a legal challenge aimed at invalidating medical marijuana initiatives that were overwhelmingly approved by voters earlier this month.

According to Judge Strong, the petitions met all constitutional and statutory requirements, making them legally sufficient under Nebraska law. This allows the law to take effect on December 12, although the decision may be appealed to the Nebraska Supreme Court.

Earlier this month, Nebraskans overwhelmingly voted in favor of legalizing medical marijuana and implementing a regulatory framework for sales, with 70% of voters supporting the initiatives. Certification of the election results is expected next week.
Continue reading

Clinical Trial Finds Combination THC and Acetazolamide Reduces Obstructive Sleep Apnea Severity

A randomized, double-blind, placebo-controlled study published in SLEEP by Oxford Academic found that a combination treatment of dronabinol (IHL-42X), a synthetic form of THC, and acetazolamide, significantly reduced the severity of obstructive sleep apnea (OSA).

Conducted by researchers from The University of Western Australia, Monash University, and several Australian hospitals, the study explored the safety and efficacy of this pharmaceutical approach for patients struggling with traditional OSA treatments.

The study enrolled participants with moderate to severe OSA, defined as having an apnea-hypopnea index (AHI) of 15 or more events per hour. Eleven participants underwent one week of nightly IHL-42X at low, medium, and high doses, as well as a placebo, with a one-week washout period between treatments. The primary outcomes measured were changes in AHI, oxygen desaturation index (ODI), daytime sleepiness (Epworth Sleepiness Scale), and mood, while adverse events (AEs) were monitored throughout.
Continue reading